MTOR and head and neck squamous cell carcinoma: We also observed that mTOR inhibitors (mTORis) display potent antitumor activity in a large variety of genetically defined and chemically induced experimental HNSCC models (13–19) as well as in our recently reported phase II clinical trial in patients with HNSCC (20).